Ubrogepant

CAT#: H319683

CAS#: 1374248-77-7

Description: Ubrogepant, also known as MK-1602, is a potent and selective oral calcitonin gene-related peptide (CGRP) receptor antagonist. Ubrogepant, sold under the trade name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine. In December 2019, the U.S. Food and Drug Administration approved Ubrelvy produced by Allergan USA, Inc. for treatment of migraine after onset.

img

Synthetic Routes

Ubrogepant - Synthetic Route 1

Ubrogepant route01

Synthetic reference

Belyk, Kevin M.; Cleator, Edward; Kuo, Shen-Chun; Maligres, Peter Emmanuel; Xiang, Bangping; Yasuda, Nobuyoshi; Yin, Jianguo. Process for preparing pyrrolo[2,3-b]pyridine derivatives as CGRP receptor antagonists. Assignee Merck Sharp & Dohme Corp., USA. 2013. WO 2013138418.

Ubrogepant - Synthetic Route 2

Ubrogepant route02

Synthetic reference

Bell, Ian M.; Fraley, Mark E.; Gallicchio, Steven N.; Ginnetti, Anthony; Mitchell, Helen J.; Paone, Daniel V.; Staas, Donnette D.; Wang, Cheng; Zartman, C. Blair; Stevenson, Heather E. Preparation of piperidinonylcarboxamideazaindane derivatives for use as CGRP receptor antagonists. Assignee Merck Sharp & Dohme Corp., USA. 2012. WO 2012064910.